FIELD: biotechnology.
SUBSTANCE: invention relates to peptide enhancers of antibody-dependent cell-line cytotoxicity (ADCC), and can be used in medicine to amplify ADCC in a combination with a therapeutic anti-cell surface antigen, indicative of a malignant growth. A fused protein consisting of a high-affinity Fc-binding domain, a high-affinity CD3-binding domain and a flexible serine-glycine linker is obtained.
EFFECT: present invention provides higher therapeutic effectiveness of antibodies by using technology of soluble universal protein-enhancer ADCC (SUAEP), id est ready-to-use adapter-like, soluble universal ADCC amplifying protein.
6 cl, 23 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| VARIANTS WITH Fc-FRAGMENT, HAVING HIGH AFFINITY TO FcRn AND HIGH AFFINITY TO AT LEAST ONE RECEPTOR OF Fc-FRAGMENT | 2018 |
|
RU2820162C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
| POLYSPECIFIC POLYPEPTIDE CONSTRUCTS WITH LIMITED BINDING TO CD3 AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2813816C2 |
| MUTANT VARIANTS OF Fc IgG1 DEVOID OF EFFECTOR FUNCTIONS | 2018 |
|
RU2764559C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| IMPROVED ANTIGEN-BINDING RECEPTORS | 2018 |
|
RU2825816C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
